Dulaglutide vs Cerebrolysin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. It is approved in many countries for stroke, traumatic brain injury, and dementia.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Cerebrolysin |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Contains multiple neurotrophic factors that promote neuroplasticity, reduce neuronal apoptosis, and support synaptic function. Has both neurotrophic and neuroprotective properties. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Clinical dosing: 10-30ml IV daily for acute conditions. Research use: 5-10ml IM daily for cognitive enhancement. Treatment courses typically last 10-20 days. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Administered via intramuscular or intravenous injection. IV administration is typically used in clinical settings. IM can be used for research purposes. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Generally well-tolerated. May cause dizziness, headache, sweating, or injection site reactions. Rare cases of agitation or confusion. |
| Best For |